



Florida Department of Health

Resources to Address Barriers to Long-Acting Injectable Antiretroviral Therapy

August 20, 2024

Presenter

LaCandria “Candy” Churchill

Development, Implementation and 340B Compliance Manager
HIV Patient Care and Treatment Access Program
Florida Department of Health

Background

Early discussions began with the Florida Ryan White Part A and B programs on long-acting injectables in 2020.

Within the Florida Comprehensive Planning Network, a Medication Access Committee (MAC) convenes on medication and insurance updates that impact people living with HIV.

Community and provider guidance is requested from the MAC and other partnerships.

Florida AIDS Drug Assistance Program added the first long-acting injectable to its formulary in 2021.


Clinical Coordination for Long-Acting Injectables



Shipping



Scheduling



Injectable
Administration



Patient Enrollment
Form

Provider Survey to Inform Barriers to Long-Acting Injectables

Z-Track
Administration
Training

Patients Enrolled
in Ryan White
Program

Refrigeration
Management

Appointment
Scheduling

Resistance
Tracking

Patient
Education
Programs

Percentage of
Clients
Interested in
Injectables

Other Limitations
for Providing
Injectable
Therapy

Five Barriers to Long-Acting Injectables



PATIENT
ADHERENCE
ISSUES



STAFF
TRAINING
ISSUES



TRANSPORTATION
ISSUES



MEDICATION
COSTS



BILLING

Resource Examples



Resources to Address Potential Barriers to Long-Acting Injectable Antiretroviral (L-AI ARV) Therapy

Oral medication	<p>For optional initial oral lead in, a practitioner would place order for initiation of Cabenuva through Provider Resources ViivConnect. A prescription needs to be sent to TheraCom for Vocabria (cabotegravir) and Edurant (rilpivirine).</p> <p>For planned missed injection, the current process is to contact ViivConnect to get information to send the prescription to TheraCom for Vocabria (the cabotegravir portion of the oral medication). The Edurant (rilpivirine) portion of the oral regimen is available for order at the client's retail pharmacy.</p>
-----------------	---

Staff Training Issues:

Area of concern	Suggestions and best practices
Staff training specific to Cabenuva and Z-track injection	There is an updated dosing and administration guideline with infographics available at Cabenuva Dosing and Admin Guide PDF Jan 2022.pdf (cabenuvahcp.com) .
Possible issues with rescheduling appropriately for the injection	Clinical support staff should be made aware of the +/- seven-day window limitation to schedule for Cabenuva injections. Include front desk staff in training on the importance of rescheduling patients receiving Cabenuva in a timely manner. If a patient cannot be reached or cancels their appointment, refer to internal processes and include seeking county health department support to locate the patient (through a linkage and engagement specialist or disease intervention specialist).
Clinical considerations for Cabenuva temperature control and administration	DO NOT TAKE THE MEDICATION OUT OF THE FRIDGE UNTIL THE PATIENT ARRIVES. Please wait 15 minutes for the medication to warm up at room temperature prior to injection administration. If you need a larger administration needle to accommodate for body size, contact Fisher Healthcare for the two-inch safety needle. Search for "2-inch safety needle."

Transportation Issues:

Area of concern	Suggestions and best practices
Transportation access and limited ability to present to clinic for follow-up	Local areas are to determine how to address transportation needs within their jurisdictions. Transportation issues are not unique to this drug and are handled differently in different areas based on available resources. Consider ride-share services available in your area. Other possible transportation services may be available through local volunteer organizations, elder care services organizations, and community and religious centers.

2

Lenacapavir Prior Authorization Form Florida AIDS Drug Assistance Program

Lenacapavir Prior Authorization Form

Instructions:

- Fax completed form and documentation to ADAP confidential fax line at 850-412-2680.
- For any questions regarding this form, please contact the HIV Medical Team at HIVMedicalTeam@flhealth.gov.

Note: Prescriber will receive a written response via fax within three business days.

PATIENT LAST NAME:	PATIENT FIRST NAME:	DATE OF BIRTH:
		/ /
PRESCRIBER NAME (first and last):		
CREDENTIALS:	<input type="checkbox"/> APRN	<input type="checkbox"/> DO <input type="checkbox"/> MD <input type="checkbox"/> PA
PRESCRIBER PHONE:	PRESCRIBER FAX:	
PRESCRIBER EMAIL:		
OFFICE CONTACT NAME /NUMBER:		

COVERAGE FOR INSURED CLIENTS ONLY

Select one of the options below.

<input type="checkbox"/>	Patient's insurance will be the primary payor and ADAP will cover copay only <ul style="list-style-type: none">• Submission of this form is not required.• You will be contacted to provide information, if needed, before a coverage determination is made.
<input type="checkbox"/>	Patient's insurance has denied coverage and ADAP will be the sole payor <ul style="list-style-type: none">• Submit documentation of insurance denial for lenacapavir• Complete remainder of this form and submit completed form and documentation as instructed above.

Important Notes:

- Florida ADAP may need to implement a patient cap
- If request is for continuation of therapy, complete patient and provider information on the top of the form and proceed to page 3
- Lenacapavir approval will be provided for a maximum of 1 year
- Provider is responsible for the care and assessment of the patient
- Provider should obtain an HIV VL 4-8 weeks after starting the lenacapavir-containing regimen and then every 3-4 months or as clinically indicated

Revised January 2024

[Home](#) » [Diseases and Conditions](#) » [AIDS](#) » Clinical Resources

Clinical Resources

GENERAL INFORMATION ▼

LONG-ACTING INJECTABLE RESOURCES ▲

- [Implementation Resources for Cabenuva Revised May 2023](#)
- [Provider Capacity Survey Results for Long-Acting Injectables](#)
- [Sunlenca Initiation Guide](#)
- [Lenacapavir Prior Authorization Form](#)

Collaboration Efforts and Process Improvement Strategies

Developing relationships with community partners

Creating multiple sessions for staff and practitioners

Providing all available resources from the manufacturer

Determining by which methods patients can receive the injectable

Creating a point of contact or a team for escalated issues

Contact Information



LaCandria “Candy” Churchill

Development, Implementation and 340B Compliance Manager
Patient Care and Treatment Access Program

HIV/AIDS Section

Bureau of Communicable Diseases

Division of Disease Control and Health Protection

Lacandria.Churchill@flhealth.gov